By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this fall, we prepared to report Phase III data for tebipenem HBr, our oral ...
Recent deals for MyoKardia and The Medicines Co. may be hard to follow, since venture investors and big pharma acquirers have largely ignored cardiovascular drugs.
With venture funding and NIH funding up in 2020, a CBRE report looked at some of the fastest-growing life science clusters in the country.
Sanofi's CSO Nabel steps down from role; BioMarin adds Eggan to head early research; Shams joins ProQR as CSO.
Lawyers at Cooley, Fenwick, Gunderson and Wilson Sonsini are all known to take stakes in some tech- and life sciences-industry clients.
It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them
Days after President Donald Trump was treated with a similar antibody therapy from Regeneron, his administration is backing another candidate being tested by British drugmaker AstraZeneca.
Rents are rising for lab space, vacancies are plunging and research and development, and employment and new development are expanding further, thanks to strong venture capital investment.